EYPT News & Events

EyePoint announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU for the treatment of diabetic macular edeme. DURAVYU is an investigational sustained delivery therapy delivering vorolanib, a selective tyrosine kinase inhibitor that brings a novel, multi-mechanism of action inhibiting VEGF-mediated vascular permeability, PDGF, and IL-6 mediated inflammation to the potential treatment of DME. The DURAVYU DME program consists of two global, randomized, double-masked, on-label aflibercept controlled non-inferiority trials assessing the safety and efficacy of DURAVYU in patients with DME, including both treatment-naive and previously treated patients. Each trial will enroll approximately 240 patients, who are randomly assigned, on Day 1, to a DURAVYU 2.7mg dose arm or the aflibercept control arm. Patients in the DURAVYU 2.7mg arm will be re-dosed every six months, starting on Day 1 of the trial. DURAVYU 2.7mg is delivered via a single standard intravitreal injection in the physician's office, similar to current standard practice with FDA approved intravitreal treatments. The primary endpoint is a non-inferior change from baseline in best corrected visual acuity to weeks 52 and 56, blended versus aflibercept control. Secondary endpoints include safety, superiority in reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections, and anatomical results as measured by optical coherence tomography. The DME pivotal program was informed by a positive End of Phase 2 meeting with the U.S. Food and Drug Administration and has alignment with both the FDA and the European Medicines Agency.

EyePoint announced that Michael Campbell has been appointed Chief Commercial Officer. Campbell will assume responsibility for EyePoint's commercial strategy and launch readiness for Duravyu, currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. Campbell will report directly to Dr. Jay Duker, President and CEO, and will serve on the executive leadership team. Prior to joining EyePoint, Campbell was the Chief Commercial Officer at Opthea

EyePoint announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 143,000 shares of EyePoint common stock to six new employees. The stock options were granted on February 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $12.94 per share, the closing price of EyePoint's common stock on February 13, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint through the applicable vesting dates.